board of directors  actinium pharmaceuticals inc atnm home about about board of directors sandesh seth chief executive officer and chairman of the board mr seth has  years experience in investment banking laidlaw  co cowen  co equity research bear stearns commonwealth associates and in the pharmaceutical industry pfizer warnerlambert smithkline in strategic planning business development and rd project management mr seth is the chairman of the board of relmada therapeutics inc a publicly listed specialty pharmaceuticals company focused on pain therapeutics mr seth has received his ms degree in pharmaceutical science from the university of oklahoma and his mba with a concentration in finance from nyu stern c david nicholson bs phd director c david nicholson bs phd is independent director of actinium pharmaceuticals inc he is senior vice president global brands rd at actavis plc previously he was on the executive committee of bayer cropscience as head of research  development responsible for the integration of the company’s rd activities into one global organization dr nicholson graduated in pharmacology earning his bsc from the university of manchester  and his phd from the university of wales  between  and  dr nicholson worked in the pharmaceutical industry for the british company beechamwülfing in gronau germany the main emphasis of his activities as group leader in a multidisciplinary project group was the development of cardiovascular drugs from  dr nicholson held various positions of increasing seniority in the uk the netherlands and the usa with organon a business unit of akzo nobel ultimately he became executive vice president research  development and member of the organon executive management committee he implemented change programs leading to maximizing effectiveness in research  development ensuring customer focus and the establishment of a competitive pipeline of innovative drugs in  dr nicholson transferred to scheringplough kenilworth new jersey usa as senior vice president responsible for global project management and drug safety from  to december  he was vice president licensing and knowledge management at merck in rahway new jersey usa reporting to the president of merck rd as an integration team member david nicholson played a role in the strategic mergers of organon biosciences the human and animal health business of dutch chemical giant akzonobel and scheringplough in  as well as of scheringplough and merck in  c david nicholson is presently on the board of multiple biotechnology companies including actinium pharmaceuticals inc committees committee role compensation committee chair audit committee member corporate governance committee member ajit shetty phd director dr shetty is a pharmaceutical industry executive with  years of experience at johnson  johnson jj and its subsidiary janssen most recently dr shetty served as the head of enterprise supply chain at jj where he was responsible for the transformation and optimization of jjs global supply chain dr shetty joined janssen pharmaceutica inc in  ultimately rising to the position of president in  where he led the establishment of janssens business in the us from  to  he was managing director of janssen pharmaceutica during this time the janssen group of companies global sales grew from  billion to  billion and from  until  he was chairman of the board of directors in dr shettys most recent role at johnson  johnson he was head of enterprise supply chain where he reported to the ceo and was responsible for the transformation and optimization of johnson  johnsons supply chain dr shetty earned a phd in metallurgy and ba natural sciences from trinity college cambridge university and a master of business administration from carnegie mellon university in  dr shetty was bestowed the title of baron by king albert ii of belgium for his exceptional merits he is a member of the board of trustees of carnegie mellon university serves on the board of governors for gs global standards in belgium and formerly served on the corporate advisory board of the john hopkins carey business school in  dr shetty was named as chairperson of the vlaams instituut voor biotechnologie vib a belgium based life sciences research institute focused on translating scientific results into pharmaceutical agricultural and industrial applications in addition he was elected manager of the year in  in flanders and received a lifetime achievement award in india in  committees committee role corporate governance committee chair audit committee member compensation committee member richard l steinhart director richard i steinhart has served as our director and chairman of the audit committee since november  mr steinhart is also a member of our compensation committee through december  mr steinhart was employed by mela sciences inc as their vice president finance and chief financial officer treasurer and secretary since april  and in april  mr steinhart received a promotion to sr vice president finance from may  until joining the company mr steinhart was a managing director of forest street capitalsae ventures a boutique investment banking venture capital and management consulting firm focused on healthcare and technology companies prior to forest street capitalsae ventures he was vice president and chief financial officer of emisphere technologies inc mr steinhart’s other experience includes seven years at cw group inc a venture capital firm focused on medical technology and biopharmaceutical companies where he was a general partner and chief financial officer until december  mr steinhart served on the board of manhattan pharmaceuticals inc a biopharmaceutical company and was chairman of its audit committee mr steinhart began his career at price waterhouse now known as pricewaterhousecoopers he holds bba and mba degrees from pace university and is a certified public accountant inactive committees committee role audit committee chair compensation committee member corporate governance committee member bone marrow transplant induction and conditioning in one iomabb actinium’s lead asset is in a pivotal phase  clinical trial as an induction and conditioning agent in patients over the age of  with relapsed or refractory acute myeloid leukemia aml prior to receiving a bone marrow transplant bmt also known as a hematopoietic stem cell transplant or hsct view highlights of key opinion leaders discussing iomabb view clinical panel discussion robust pipeline actinium pharmaceuticals drug development pipeline features iomabb which is in a pivotal phase  clinical trial actimaba which is in a phase  clinical trial and actimabm currently in a phase  clinical trial actinium is focused on continuing to expand its drug development pipeline by leveraging its apit technology platform and domain expertise view pipeline email sign up receive the latest news events and updates sign up now sandesh c seth msmba executive profile  biography  bloomberg july    am et biotechnology company overview of actinium pharmaceuticals inc snapshotpeople  overviewboard memberscommittees executive profile sandesh c seth msmbaexecutive chairman  ceo actinium pharmaceuticals incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background mr sandesh c seth ms mba has been chief executive officer of actinium pharmaceuticals inc since june   mr seth serves as the head of healthcare investment banking at laidlaw  company uk ltd mr seth has been the executive chairman and director of actinium pharmaceuticals inc since october  and march  respectively prior to this he served as the managing partner at amerasia capital partners llc he also founded the firm prior to that  he served as an investment banker at sg cowen  co llc prior to that he served as an equity analyst at bear stearns companies inc research division prior to that mr seth was at commonwealth associates inc where he covered the life sciences sector he served as a research analyst at commonwealth associates lp research division as part of his financial services experience he was also involved with various strategic initiatives such as mergers and acquisitions leveraged and management buyouts and licensing and joint ventures including the  billion merger of pfizer and warnerlambert and the  billion merger of pharmacia  upjohn with monsanto in addition he has over seven years of pharmaceutical industry experience including rd project management marketing and strategic planning at smithkline beecham inc warnerlambert  co and pfizer inc respectively he served as the chairman of relmada therapeutics inc from june  to june   he served as director of relmada therapeutics inc from october  to june   and served as its lead director since january  he served as a director of cactus ventures inc since december   he has over  years of experience in merchant and investment banking equity research at cowen  co bear stearns and commonwealth associates and in the pharma industry at pfizer warnerlambert and smithkline mr seth has published and presented several scientific articles and was awarded the university regents award for research excellence at the university of oklahoma he was designated as regulatory affairs certified by the regulatory affairs professionals society which signified proficiency with us fda regulations mr seth is also registered with the nasd as a general securities representative series   and  he has an mba in finance from new york university an ms in the pharmaceutical sciences from the university of oklahoma health center and a bsc in chemistry from bombay universityread full background corporate headquarters  madison avenuenew york new york united statesphone fax  board members memberships directoractinium corporationpresentexecutive chairman  ceoactinium pharmaceuticals inc education mba new york universityms university of oklahomabs university of mumbai other affiliations new york universityuniversity of oklahomauniversity of mumbairelmada therapeutics incbear stearns companies inc research divisionamerasia capital partners llccactus ventures inccommonwealth associates lp research divisionactinium corporation annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation there is no total compensation data available request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact actinium pharmaceuticals inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close expert  sandesh seth streetwise reports the gold report the energy report the life sciences report the gold reportthe energy reportthe life sciences report sector expert sandesh seth actinium pharmaceuticals inc sandesh seth is the executive chairman of actinium pharmaceuticals inc a biopharmaceutical company developing innovative targeted payload radioimmunotherapeutics for the treatment of advanced cancers mr seth has plus years of healthcare industry experience that encompasses in investment banking cowen  co equity research bear stearns commonwealth associates and the pharma industry pfizer warnerlambert smithkline in strategic planning business development and rd project management in addition mr seth is the chairman of relmada therapeutics inc a publicly listed specialty pharmaceuticals company focused on pain therapeutics he has an ms in pharmaceutical science from the university of oklahoma and an mba in finance from new york universitys leonard stern school of business subscribe tostreetwise reports recent interviews radioimmunotherapy  actinium sets eyes on bone marrow transplant and aml with laterstage programs  radioimmunotherapy is experiencing a renaissance and actinium pharmaceuticals inc is in position to benefit according to company executive chairman sandesh seth with two assets targeting treatment of aml in older adults in clinical trials and a platform primed to nuke cancer the company has a number of milestones in its near future that investors should be watching due to permission requirements not all quotes are shown subscribeaboutdisclaimercontactsponsorshipsyndicationcareerspolicies   streetwise reports all rights reserved streetwise reports is registered with the us patent and trademark office actinium pharmaceuticals announces appointment of sandesh seth as chief executive officer  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street actinium pharmaceuticals announces appointment of sandesh seth as chief executive officer globenewswire jun    am edt  mr seth to serve as chief executive officer and chairman of the board of directors  independent director dr ajit shetty appointed to the companys corporate governance audit and compensation committees new york june   globe newswire  actinium pharmaceuticals inc nyse mktatnm actinium or the company a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers announced today that actiniums board of directors unanimously appointed mr seth as chief executive officer effective immediately  mr seth will continue his role as chairman that commenced in october of   in addition steve oloughlin has been appointed principal financial and accounting officer as of may   actiniums board of directors released a statement that said as executive chairman mr seth has been dedicated to advancing the goals of actinium pharmaceuticals with a focus on patient outcomes and shareholder value  under mr seths guidance the company has made tremendous progress recently which includes hiring of key personnel such as our chief medical officer dr mark berger vpclinical and commercial strategy steven price and several senior members of the core manufacturing team  mr seths initiatives have sharply focused the clinical organization that is driving progress of our clinical trials  in addition key intellectual property is being filed and value enhancing initiatives are being progressed as he assembles a robust team that is capable of generating value  we are excited to announce the appointment of mr seth as the companys chief executive officer as we have great confidence in his ability to lead actinium in its next phase of development which includes continued development of our iomabb actimaba and actimabm drug candidates as well as our alpha particle technology platform  in doing so we believe actinium will establish itself as a leader at the intersection of radioimmunotherapy and oncology if you liked this article you might like anthem denies cigna breakup fee as merger bid crumbles anthems statement comes a day after a delaware judge declined to grant an extension to anthems takeover effort tony owusu may    pm edt these  stocks under  could explode up soon heres a technical look at how to trade several under stocks triggering breakout trades roberto pedone feb    pm est these  stocks are breaking out heres how to trade five stocks that are ready to break out and trade higher from current levels roberto pedone aug    pm edt friday smallcap focus actinium fdas approval of one of its primary drug candidates was crucial bret jensen dec    am est trending amazon and general electric are fridays smoking hot tickers amzn tsla sbux ge aapl amazon and starbucks team up to take down nasdaq here is why jim cramer doesnt want to buy more starbucks shares for action alerts plus apple investing billions in oled display buy chevron exxon mobil on solid dividends chart pinpoints when to load advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers atnm company profile  executives  actinium pharmaceuticals inc  wall street journal dow jones a news corp company news corp is a network of leading companies in the worlds of diversified media news education and information services dow jones barrons bigcharts djx dow jones newswires factiva financial news mansion global marketwatch newsmart newsplus private markets risk  compliance wsjcom wsj pro wsj conference wsj video news corp big decisions business spectator checkout harper collins new york post proptiger rea realtorcom storyful the australian the sun the times djia ▲     sp  ▲     nasdaq ▲     us  yr ▲  yield    crude oil ▲     euro ▲     subscribe now sign in the wall street journal us edition us asia europe india  china  japan july   todays paper sections my journal home world us politics economy business tech markets opinion arts life real estate todays paper show all sections hide all sections world home africa asia canada china europe latin america middle east economy world video us home economy law new york politics real time economics washington wire journal report us video whats news podcast politics home washington wire politics video wsjnbc news poll economy home real time economics economic forecasting survey economy video business home management techwsjd aerospace  defense autos  transportation commercial real estate consumer products energy entrepreneurship financial services food  services health care hospitality law manufacturing media  marketing natural resources retail cfo journal cio journal cmo today logistics report risk  compliance heard on the street business video journal report business podcast tech home cio journal geoffrey fowler christopher mims joanna stern li yuan billion dollar startup club tech video tech podcast startup stock trader markets home bonds commercial real estate commodities  futures currencies deals financial services funds stocks your money heard on the street moneybeat wealth adviser ahead of the tape cfo journal journal report market data markets video markets podcast moneybeat podcast watching your wealth podcast opinion home james freeman william a galston daniel henninger holman w jenkins william mcgurn peggy noonan mary anastasia ogrady jason riley kimberley a strassel books film television theater art masterpiece series music dance opera exhibition cultural commentary editorials commentary letters to the editor the weekend interview potomac watch podcast foreign edition podcast opinion video notable  quotable best of the web newsletter morning editorial report newsletter arts home books film television theater art masterpiece series arts video wsj magazine life home careers cars food  drink health ideas real estate science sports style  fashion travel life video wsj magazine wsj puzzles the future of everything real estate home commercial real estate house of the day mansion real estate video hide all sections aim higher reach further get the wall street journal  for  weeks subscribe now sign in reveal navigation options subscribe sign in actinium pharmaceuticals inc atnm us nyse american search view all companies real time  am edt   usd   volume  volume   day avg vol   day range     week range        d  d  m  m ytd  y  y   advanced charting compare compare to benchmark djia sp  global dow nasdaq health carelife sciences compare to add open  prior close    day atnm  djia  russell k  health carelife sciences  overview profile key people overview profile financials income statement balance sheet cash flow research  ratings historical prices options advanced charting sandesh seth  executive chairman  chief executive officer actinium pharmaceuticals inc mr sandesh seth is executive chairman  chief executive officer at actinium pharmaceuticals inc and managing partner at jamess capital group llc mr seth was previously employed as lead director by camp nine inc lead director by relmada therapeutics inc old chairman by relmada therapeutics inc and headhealthcare investment banking by laidlaw  co uk ltd he also served on the board at cactus ventures inc and actinium pharmaceuticals inc old he received his undergraduate degree from the university of mumbai a graduate degree from the university of oklahoma health sciences center and an mba from the leonard n stern school of business news actinium pharmaceuticals incatnm significant news only  hours ago dow jones newswires actinium pharmaceuticals files k  entry into definitive agreement dow jones newswires  hours ago dow jones newswires actinium pharmaceuticals files k  regulation fd dow jones newswires  hours ago press release actinium announces pricing of public offering of common stock and warrants to purchase common stock press release  hours ago press release actinium announces proposed public offering of common stock and warrants to purchase stock press release  press release stock performance review on biotech industry  biopharmx ampliphi biosciences actinium pharma and matinas biopharma press release  press release actinium pharmaceuticals to host webinar focused on actimaba and recent developments related to cd targeted aml therapies on july   at  am et press release  press release actinium pharmaceuticals to host webinar focused on actimaba and recent developments related to cd targeted aml therapies on july   at  am et press release  dow jones newswires actinium pharmaceuticals files k  entry into definitive agreement dow jones newswires  dow jones newswires actinium pharmaceuticals files k  changes exec mgmt dow jones newswires  dow jones newswires actinium pharmaceuticals files k  entry into definitive agreement dow jones newswires  press release actinium pharmaceuticals issues midyear letter to shareholders highlighting accomplishments and significant value enumerating catalysts over the coming quarters press release  press release actinium pharmaceuticals announces appointment of nitya ray phd as executive vicepresident head of product development manufacturing and supply chain and other key hires in its product development and manufacturing teams press release  press release actinium pharmaceuticals to host webinar on june th to update on pivotal phase  sierra clinical trial for iomabb press release  dow jones newswires actinium pharmaceuticals files k  changes exec mgmt dow jones newswires  press release actinium pharmaceuticals announces appointment of sandesh seth as chief executive officer press release  dow jones newswires actinium pharmaceuticals files k  entry into definitive agreement dow jones newswires  press release actinium pharmaceuticals highlights presence at upcoming society of nuclear medicine and molecular imaging annual meeting press release  press release update  actinium pharmaceuticals to host webinar on june th to update on pivotal phase  sierra clinical trial for iomabb press release  press release actinium pharmaceuticals to host webinar on june th to update on pivotal phase  sierra clinical trial for iomabb press release  press release actinium pharmaceuticals granted orphan designation from the european medicines agency for actimaba press release  press release actinium pharmaceuticals to present actimaba data at the th international symposium on targeted alpha therapy press release  press release research reports initiation on biotech stocks  agenus athersys actinium pharma and aveo pharma press release  press release actinium pharmaceuticals announces appointment of hematology expert dr richard stone of the danafarber cancer institute to its scientific advisory board press release  dow jones newswires actinium pharmaceuticals files k  changes exec mgmt dow jones newswires  dow jones newswires actinium pharmaceuticals files k  changes exec mgmt dow jones newswires  dow jones newswires actinium pharmaceuticals files k  entry into definitive agreement dow jones newswires  press release actinium pharmaceuticals receives clearance from health canada to initiate pivotal phase  sierra trial of iomabb press release load more all company executives actinium pharmaceuticals inc sandesh seth  executive chairman  chief executive officer steve oloughlin chief financial  accounting officer mark s berger chief medical officer nitya g ray  executive vice president maria gomes nunes managerquality control  assurance jeannine larrieux directoranalytical development laura chen senior quality assurance specialist david gould senior vpfinance  corporate development rowena choudrie directorpharmaceutical product development corey sohmer vice presidentfinance  business development ajit s shetty director evan smith vice presidentinvestor relations  finance richard m stone chief of staff  program director c david nicholson  independent director richard i steinhart  independent director expand advertisement notes  data providers realtime us stock quotes reflect trades reported through nasdaq only international stock quotes are delayed as per exchange requirements indexes may be realtime or delayed refer to time stamps on index quote pages for information on delay times quote data except us stocks provided by six financial information data is provided as is for informational purposes only and is not intended for trading purposes six financial information a does not make any express or implied warranties of any kind regarding the data including without limitation any warranty of merchantability or fitness for a particular purpose or use and b shall not be liable for any errors incompleteness interruption or delay action taken in reliance on any data or for any damages resulting therefrom data may be intentionally delayed pursuant to supplier requirements all of the mutual fund and etf information contained in this display was supplied by lipper a thomson reuters company subject to the following copyright  thomson reuters all rights reserved any copying republication or redistribution of lipper content including by caching framing or similar means is expressly prohibited without the prior written consent of lipper lipper shall not be liable for any errors or delays in the content or for any actions taken in reliance thereon bond quotes are updated in realtime source tullett prebon currency quotes are updated in realtime source tullet prebon fundamental company data and analyst estimates provided by factset copyright factset research systems inc all rights reserved advertisement atnm sandesh seth insider trades for actinium pharmaceuticals inc x tweet share this bulletin get news bulletins by email bulletin pentagon confirms detection of north korea missile launch friday » investor alert new york markets close in market snapshot winners and losers expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close actinium pharmaceuticals inc nyse american atnm go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus actinium pharmaceuticals inc market open  real time quotes jul    am atnm quoteszigmancomposite   change   volume volume m real time quotes quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual sandesh seth mr sandesh seth is executive chairman  chief executive officer at actinium pharmaceuticals inc and managing partner at jamess capital group llc mr seth was previously employed as lead director by camp nine inc lead director by relmada therapeutics inc old chairman by relmada therapeutics inc and headhealthcare investment banking by laidlaw  co uk ltd he also served on the board at cactus ventures inc and actinium pharmaceuticals inc old he received his undergraduate degree from the university of mumbai a graduate degree from the university of oklahoma health sciences center and an mba from the leonard n stern school of business transactions date shares transaction value     acquisition at  per share      acquisition at  per share      acquisition at  per share      acquisition at  per share      acquisition at  per share      acquisition at  per share      acquisition at  per share      acquisition at  per share      acquisition at  per share      award at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives mr sandesh seth executive chairman  chief executive officer mr steve oloughlin chief financial  accounting officer dr mark s berger chief medical officer dr nitya g ray executive vice president dr maria gomes nunes managerquality control  assurance dr jeannine larrieux directoranalytical development ms laura chen senior quality assurance specialist dr david gould senior vpfinance  corporate development ms rowena choudrie directorpharmaceutical product development mr corey sohmer vice presidentfinance  business development dr ajit s shetty director mr evan smith vice presidentinvestor relations  finance dr richard m stone chief of staff  program director dr c david nicholson independent director mr richard i steinhart independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york open marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest ahere’s one trump fan who might make you some money awhat the solar eclipse on aug  will mean for stocks ayou’ll save money on gas with the tesla model  but you may end up paying more elsewhere asurprise those ‘great’ companies generally turn out to be meh  or duds athis quant pro and card counter says gambling can make you a better investor awatch out ‘kids’ are making the most money in this stock market athis basic balanced index fund is beating the hedge fund averages agold prices trade near session highs after reports of missile test in north korea aaug gold climbs by  or  to oz aweekend roundup amazon’s spending  surviving amazon  caterpillar’s comeback atesla’s model  will be launched with panacheand a partylater friday awhat we can learn about dealing with setbacks at work from the obamacare repeal failure awhite house should tighten sanctions on north korea experts say awhat is an ico aone way you’re paying creditcard fees even if you don’t have a card astock market edges lower on track for weekly losses aoil sets sights on biggest weekly gain of the year aupdate invisalign maker align stocks surge  after earnings blow past estimates aairbus to sell plant holdings to motorola aamerican airlines profit falls unit revenue gains loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft seth sandesh  the wall street transcript sandesh seth sandesh seth is the chairman of actinium pharmaceuticals inc he has plus years’ experience in merchant and investment banking equity research — laidlaw  co uk ltd cowen  co bear stearns commonwealth associates — and in the pharma industry — pfizer warnerlambert smithkline — in strategic planning business development and rd project management mr seth has an mba in finance from new york university an ms in the pharmaceutical sciences from the university of oklahoma health center and a bs in chemistry from bombay university in addition mr seth is also head of healthcare investment banking at laidlaw  co uk ltd a fullservice investment banking and brokerage firm and a director of relmada therapeutics inc a public specialty pharmaceuticals company related interviewsinterview with the chairman actinium pharmaceuticals inc atnmaugust   cartlatest newsall american usc footbal player joseph m boskovich jr now picks all american value stocks for his clientspaul hogan picks tech dividend growers microchip technology nasdaqmchp xilinx nasdaqxlnx and versum materials nysevsm gallons of water to produce a mcdonalds nysemcd quarter pounder how will investors profitthe wall street transcript is a completely unique resource for investors and business researchersover  ceo equity analyst and money manager interviewssubscribe nowsign up for newsletter weekly email with new indepth interviews email most popular interviewsbuilding diversified portfolios with quality global equitiesgregory d padillaalberto jimenez crespo published july   in investing strategiescompanies covered amzn  aapl mu whr kimbera gs vod ppg shw viv pey buy building accountability and avoiding mistakes through the decision processdean pagonis published july   in investing strategiescompanies covered cmp sbh amzn ulta cvs lrlcy kmb www sdf buy finding optimal balance sheets by utilizing high yield market expertisezach miller published july   in investing strategiescompanies covered lsxmk siri bll chtr armk buy most popular reportsinvesting strategies published july  buy wireless communications  telecom published july  buy investing strategies published july  buy  top company interviews register for a free account to gain greater access to the wall street transcript right now ceo interviewsinterview with the president and ceo lumos networks corp nasdaqlmosinterview with the corporate vp of business development strategy and investor relations dsp group inc nasdaqdspginterview with the ceo and director tactile systems technology inc nasdaqtcmd sector roundtablesnatural gas weighs heavy on ep nearterm prospectsroundtable forumoptimism despite uncertainty in forprofit educationroundtable foruma shift in focus to natural gas from oil money manager interviewsbuilding diversified portfolios with quality global equitiesbuilding accountability and avoiding mistakes through the decision processfinding optimal balance sheets by utilizing high yield market expertise analyst interviewsanalyzing the secular drivers within communications infrastructure and telecomsatellite companies benefiting from growth in data trafficincreased focus on content as consumers shift to digital consumption subscribe today since   the wall street transcript  terms and conditions privacy policy   httpswwwtwstcomwpadminadminajaxphp pin it on pinterest share this twitter facebook google gmail linkedin × join now for free already a member first name last name email address  create new account or create an account with a social network join with facebook join with twitter join with google username or email address  password  loginjoin now  forgot password or login using a social network log in with facebook log in with twitter log in with google actinium pharmaceuticals announces appointment of sandesh seth as chief executive officer nyseatnm english français register sign in actinium pharmaceuticals announces appointment of sandesh seth as chief executive officer june    et  source actinium pharmaceuticals  mr seth to serve as chief executive officer and chairman of the board of directors  independent director dr ajit shetty appointed to the company’s corporate governance audit and compensation committees new york june   globe newswire  actinium pharmaceuticals inc nyse mktatnm actinium or the company a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers announced today that actinium’s board of directors unanimously appointed mr seth as chief executive officer effective immediately  mr seth will continue his role as chairman that commenced in october of   in addition steve o’loughlin has been appointed principal financial and accounting officer as of may   actinium’s board of directors released a statement that said “as executive chairman mr seth has been dedicated to advancing the goals of actinium pharmaceuticals with a focus on patient outcomes and shareholder value  under mr seth’s guidance the company has made tremendous progress recently which includes hiring of key personnel such as our chief medical officer dr mark berger vpclinical and commercial strategy steven price and several senior members of the core manufacturing team  mr seth’s initiatives have sharply focused the clinical organization that is driving progress of our clinical trials  in addition key intellectual property is being filed and value enhancing initiatives are being progressed as he assembles a robust team that is capable of generating value  we are excited to announce the appointment of mr seth as the company’s chief executive officer as we have great confidence in his ability to lead actinium in its next phase of development which includes continued development of our iomabb actimaba and actimabm drug candidates as well as our alpha particle technology platform  in doing so we believe actinium will establish itself as a leader at the intersection of radioimmunotherapy and oncology” sandesh seth said “it is an honor to be appointed chief executive officer of actinium at such an exciting time for the company  our radioimmunotherapies hold tremendous potential for extremely sick cancer patients who lack effective treatment options especially in the areas of bone marrow transplant acute myeloid leukemia and multiple myeloma  i am excited to continue to work with the everstronger actinium team to execute our vision of building an innovative biopharmaceutical company that transforms the treatment of patients with radioimmunotherapies” the company also announced that dr ajit shetty has been appointed to the company’s corporate governance chairman audit and compensation committees in the place of mr sergio traversa who has resigned from actinium’s board of directors  dr shetty joined actinium’s board of directors as an independent director in march of   dr shetty spent  years in key executive roles at janssen and johnson  johnson  from  to  he served as president of janssen pharmaceutica inc where he established janssen’s us business  from  to  he served as managing director and oversaw janssen group of companies’ growth in global sales from  billion to   billion and from  to  he served as chairman of the board of directors most recently dr shetty was head of enterprise supply chain at johnson  johnson  in addition the company appointed steve o’loughlin principal financial and accounting officer on may    mr o’loughlin joined actinium in october  and has served as vice president corporate finance and development about actinium pharmaceuticals inc actinium pharmaceuticals inc is a biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options actiniums proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively the companys lead product candidate iomabb is designed to be used upon approval in preparing patients for a hematopoietic stem cell transplant commonly referred to as bone marrow transplant a bone marrow transplant is often the only potential cure for patients with bloodborne cancers but the current standard preparation for a transplant requires chemotherapy andor total body irradiation that result in significant toxicities actinium believes iomabb will enable a faster and less toxic preparation of patients seeking a bone marrow transplant leading to increase transplant success and survival rates the company is currently conducting a single pivotal patient multicenter phase  clinical study of iomabb in patients with active relapsed or refractory acute myeloid leukemia aml age  and older the companys second product candidate actimaba is currently in a multicenter openlabel patient phase  trial for patients newly diagnosed with aml age  and over actimaba is being developed to induce remissions in elderly patients with aml who lack effective treatment options and often cannot tolerate the toxicities of standard frontline therapies in addition actinium is developing actimabm which is being studied in patients with relapsed or refractory multiple myeloma in a phase  clinical trial actinium is also utilizing its alphaparticle immunotherapy apit technology platform to generate new drug candidates based on antibodies linked to the element actinium that are directed at various cancers that are bloodborne or form solid tumors actinium pharmaceuticals is based in new york ny to learn more about actinium pharmaceuticals please visit wwwactiniumpharmacom and to follow actiniumpharma on twitter please visit wwwtwittercomactiniumpharma forwardlooking statements for actinium pharmaceuticals inc  this news release contains forwardlooking statements as defined in the private securities litigation reform act of  these statements are based on managements current expectations and involve risks and uncertainties which may cause actual results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential or financial performance no forwardlooking statement can be guaranteed and actual results may differ materially from those projected actinium pharmaceuticals undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwiseactinium pharmaceuticals inc steve oloughlin vice president finance and corporate development soloughlinactiniumpharmacom related articles other press releases by actinium pharmaceuticals actinium announces pricing of public offering of common stock and warrants to purchase common stock july    actinium announces proposed public offering of common stock and warrants to purchase stock july    actinium pharmaceuticals to host webinar focused on actimaba and recent developments related to cd targeted aml therapies on july   at  am et july    actinium pharmaceuticals to host webinar focused on actimaba and recent developments related to cd targeted aml therapies on july   at  am et july    actinium pharmaceuticals issues midyear letter to shareholders highlighting accomplishments and significant value enumerating catalysts over the coming quarters june     other news releases in directors and officers in the last  days profile actinium pharmaceuticals   subscribe via rss  subscribe via atom  javascript new york new york united states contact data actinium pharmaceuticals inc steve oloughlin vice president finance and corporate development soloughlinactiniumpharmacom contact with a reader account its easy to send email directly to the contact for this release sign up today for your free reader account already have an account log in here media files actinium pharmaceuticals logo logo url  copy the link below formats available original medium small tags acute myeloid leukemia bmt tandem bone marrow transplant hematology leukemia oncology radioimmunotherapy stem cell transplant newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved